Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens

Liver Transplantation

Volumn 14, Issue 5, 2008, Pages 651-659

  Dubay, Derek ^a   Smith, Rob J ^a   Qiu, Kenneth G ^a   Levy, Gary A ^a   Lilly, Leslie ^a   Therapondos, George ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CHRONIC GRAFT REJECTION; CHRONIC KIDNEY DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GOUT; GRAFT FAILURE; HERNIA; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LEG EDEMA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORBIDITY; MOUTH ULCER; MYALGIA; NEPHROLITHIASIS; OSTEOPENIA; PARESTHESIA; PNEUMONIA; POSTOPERATIVE CARE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; SKIN MANIFESTATION; TREATMENT DURATION;

ADULT; AGED; ANTIMETABOLITES; CALCINEURIN; CASE-CONTROL STUDIES; CREATININE; CYCLOSPORINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 43849094781     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21429     Document Type: Article

References (22)

1. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-940.
2. Pawarode A, Fine DM, Thuluvath PJ. Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003;9:741-747.
3. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998;66: 59-66.
4. Velidedeoglu E, Crawford MD, Desai NM, Campos L, Abt PL, Markmann JW, et al. Predictors of late kidney dysfunction post-liver transplantation. Transplant Proc 2002;34: 3315-3316.
5. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996; 62:364-370.
6. Wilkinson A, Pham PT. Kidney dysfunction in the recipients of liver transplants. Liver Transpl 2005;11(suppl 2): S47-S51.
7. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003;35(suppl):Sl93-S200.
8. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995;17:660-665.
9. Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49:209-216.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976,16:31-41.
11. Campistol JM, Sacks MH. Mechanisms of nephrotoxicity. Transplantation 2000;69(suppl):S5-S10.
12. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxocity. Transplantation 2000;69(suppl):S11-S13.
13. Sanchez EQ, Martin AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM, et al. Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc 2005;37: 4416-4423.
14. Montalbano M, Neff GW, Yamashiki N, Meyer D, Bettiol M, Slapak-Green G, et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004;78:264-268.
15. Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, et al. Calcineurin inhibitor-induced chronic nephrotoxocity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002;16(suppl 7):49-51.
16. Neff GW, Montalbano, M, Slapak-Green G, Meyer D, Berney T, Safdar K, et al. Strolimus therapy in orthotopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency. Transplant Proc 2003;35: 3029-3031.
17. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003;9:126-129.
18. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003;9:1079-1085.
19. Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007;13:658-664.
20. Backman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattstrom C. Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus. Clin Transplant 2006;20:336-339.
21. Dhir R, Quinn MK, Dennis V, Vogt D, Henderson M, Carey W, et al. Conversion from a calcineurin inhibitor to sirolimus in liver transplant recipients with chronic renal insufficiency. Hepatology 2002;36:185A.
22. Campbell MS, Rai J, Kozin E, Bloom RD, Markmann JF, Olthoff KM, et al. Effects of sirolimus vs. calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation. Clin Transplant 2007;21:377-384.